Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids.
Immunoreactivity for fascin, an actin-bundling protein related to cell motility, has been reported in breast, ovary, pancreas, skin, and non-small cell carcinomas, and associated with more advanced disease stage and poorer prognosis. Data on pulmonary neuroendocrine (NE) tumors, however, are lacking. We evaluated the expression of fascin by immunohistochemistry--using two different monoclonal antibodies--in surgical specimens of pulmonary NE tumors of all the diverse histological types from 128 consecutive patients recruited between 1987 and 2001, and investigated its relationship with the presence of lymph node metastases. Overall, fascin immunoreactivity was detected in 5% of 38 typical carcinoids (TC), 35% of 23 atypical carcinoids (AC), 83% of 40 large-cell neuroendocrine carcinomas (LCNEC), and 100% of 27 small-cell lung carcinomas (SCLC) (P<0.001), Normal NE cells or hyperplastic NE tumorlets were consistently unreactive. No statistically significant differences in fascin immunoreactivity were found between the two antibodies. In TC and AC but not high-grade NE tumors, fascin immunoreactivity closely correlated with the occurrence of lymph node metastases, the pN class and the number of involved lymph nodes (P<0.001). It was also significantly associated with an increased proliferative activity (Ki-67 labeling index >5%) (P=0.020), and with either down-regulation or altered subcellular compartmentalization of E-cadherin (P<0.001) and CD99 (P=0.030), two cell adhesion complexes in pulmonary NE tumors. At multivariate analysis, only fascin emerged as an independent predictor of lymph node metastases in this tumor group (HR 30.28; 95% confidence intervals: 1.59-574.49; P=0.023). This study indicates that fascin immunoreactivity may identify subsets of pulmonary carcinoid patients with different metastatic potential to regional lymph nodes. Targeting the fascin pathway could be a novel therapeutic strategy of pulmonary carcinoids.
Pelosi
Giuseppe
G
Department of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Via G. Ripamonti, 435, I-20141 Milan, Italy. guiseppe.pelosi@ieo.it
Pasini
Felice
F
Fraggetta
Filippo
F
Pastorino
Ugo
U
Iannucci
Antonio
A
Maisonneuve
Patrick
P
Arrigoni
Gianluigi
G
De Manzoni
Giovanni
G
Bresaola
Enrica
E
Viale
Giuseppe
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D002276:Carcinoid Tumor / Q000473:pathology*; D018288:Carcinoma, Small Cell / Q000473:pathology*; D002352:Carrier Proteins / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D008840:Microfilament Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000473:pathology*; D011379:Prognosis; D011446:Prospective Studies; D012680:Sensitivity and Specificity
D000911:Antibodies, Monoclonal; D002352:Carrier Proteins; D008840:Microfilament Proteins; C020324:fascin